Denali Therapeutics Inc

2026-09-08 19:36; UTC

Denali Therapeutics Inc's shares are lower today, following a recent low of -2.15%. The stock remains below its 20-day moving average.

2026-09-03 19:36; UTC

Denali Therapeutics Inc. shares are lower today, continuing a six-session decline amid no specific news. Earlier, the stock peaked before declining.

2026-08-28 20:08; UTC

Denali Therapeutics shares are lower today, reflecting broader market trends amid rising U.S. Treasury yields and inflation concerns. The stock remains below its 20-day moving average.

2026-08-25 20:07; UTC

B. Riley analyst raised Denali Therapeutics Inc's price target to $30.00 while maintaining a Buy rating, coinciding with shares advancing since Monday's close.

2026-08-24 22:46; UTC

Denali Therapeutics Inc's shares are higher in after-market trading, reflecting a cumulative gain since Monday's close. No specific news was identified for this movement.

2026-08-20 19:16; UTC

Denali Therapeutics Inc shares are lower today, reflecting broader market trends. The stock has declined since Wednesday amid volatility in biotech and small-cap indices.

2026-08-19 20:02; UTC

DNLI is higher Wednesday, recovering with the SPDR S&P Biotech ETF.

2026-08-17 19:36; UTC

Denali Therapeutics Inc is trading higher today, supported by gains in the biotechnology sector. The stock remains near its 20-day moving average.

2026-08-13 19:36; UTC

Denali Therapeutics reported Q2 revenue of $3.6 million from AVLAYAH, but shares are lower despite expectations for growth in Q3.

2026-08-12 19:36; UTC

Denali Therapeutics Inc. shares are higher Wednesday, buoyed by positive market sentiment following a modest rise in the core Consumer Price Index.

2026-08-11 23:21; UTC

Denali Therapeutics Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

2026-08-10 19:36; UTC

Denali Therapeutics Inc shares declined during Monday's session, tracking broader market trends as the Russell 2000 Index fell. Energy market volatility also influenced the move.

2026-08-07 19:26; UTC

Denali Therapeutics shares are lower after a $127.6 million net loss in Q2, missing revenue expectations despite a price target increase from UBS to $34.

2026-08-06 21:03; UTC

Denali Therapeutics shares rise in after-market hours following strong revenue from AVLAYAH and plans to advance Alzheimer's programs despite an EPS miss.

2026-08-03 19:46; UTC

Denali Therapeutics received FDA orphan designation for its progranulin therapy for frontotemporal dementia, contributing to a modest rise in shares since Friday's close.

2026-07-31 20:02; UTC

Denali Therapeutics Inc shares are lower today amid a broader decline in the Biotechnology sub-sector and the Russell 2000 Index.

2026-07-30 19:18; UTC

Denali Therapeutics Inc shares are higher, reflecting positive sentiment in the biotech sector amid gains in the broader market and a volatile prior session.

2026-07-29 22:01; UTC

Denali Therapeutics Inc remains unchanged in after-market hours with no specific news. Broader market concerns stem from geopolitical tensions and upcoming Fed decisions.

2026-07-28 18:46; UTC

Denali Therapeutics Inc shares are higher today, though no specific news explains the movement. The stock remains below its 20-day moving average.

2026-07-27 19:56; UTC

Denali Therapeutics Inc is trading higher today, reflecting a notable increase since Friday's close. The stock peaked early before a slight pullback.

2026-07-24 19:26; UTC

Denali Therapeutics Inc shares are lower following first-quarter results, continuing a decline amid broader market weakness and a drop in crude oil prices.

2026-07-22 17:46; UTC

Denali Therapeutics shares are lower, reflecting broader market trends amid a decline in the Russell 2000 Index. The stock remains below its 20-day moving average.

2026-07-21 17:36; UTC

Denali Therapeutics Inc is higher today, recovering from an earlier dip amid positive market sentiment driven by gains in the Russell 2000 and Nasdaq 100 indices.

2026-07-20 23:41; UTC

Denali Therapeutics Inc. gained in after-market trading, reflecting a broader trend among correlated assets like Beam Therapeutics Inc. Shares remain below the 20-day moving average.